Company intelligence / Profile preview

Libertas International

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

Gusacitinib showed statistically significant and potentially clinically meaningful improvement across both primary and secondary endpoints in a phase 2b study for chronic hand eczema at 80mg dose and was well tolerated[7]

Therapeutic areas: Dermatology
Modalities: Small molecule
Industry: Biotech

Partnerships

Sanofi (licensed gusacitinib in June 2025)[1][2]

Beyond the preview

Go deeper on Libertas International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Libertas International.

Explore the full profile